FDA still skeptical of ALS drug ahead of high-stakes meeting

Sep 1, 2022, 10:27 PM | Updated: Sep 2, 2022, 2:13 pm
This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin K...

This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. On Friday, Sept. 2, 2022, federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they're set to give its maker, Amylyx, a rare second chance to make its case publicly. (Amylyx via AP)

(Amylyx via AP)

WASHINGTON (AP) — Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they prepare to give its drugmaker a rare second opportunity to make a public case for the treatment.

Amylyx Pharmaceuticals’ experimental drug has become a rallying cause for patients with the deadly neurodegenerative disease, their families and members of Congress who are pushing the FDA to approve the drug.

But regulators said Friday that the drugmaker’s new analyses are not “sufficiently independent or persuasive” to establish effectiveness. The agency posted its review ahead of a Wednesday meeting of its outside advisers, who will vote on whether to recommend approval.

In March, the same panel of neurological experts voted 6-4 that the company’s data failed to show a convincing benefit for ALS, or amyotrophic lateral sclerosis. It’s extremely rare for the FDA to call a second review meeting after its advisers have already voted.

The FDA will ask the panel to review several new statistical analyses, which the company says strengthen the case that its drug prolongs life and delays hospitalization and other severe complications. The FDA says the experts can take into account “the unmet need in ALS,” the disease’s seriousness and other factors specific to the terminal diseases.

Elsewhere in its review the FDA detailed the flexibility it can apply to drug approval decisions, particularly for deadly diseases, which suggests “there is a chance that the FDA is still looking for a way to approve the product,” SVB analyst Marc Goodman wrote in a note to investors. He gives Amylyx a 50% chance of approval.

ALS destroys nerve cells needed to walk, talk, swallow and — eventually — breathe. There is no cure and most people die within three to five years.

The FDA’s review reflects some of the biggest questions facing the agency, including: How strict should it be in enforcing approval standards for drugs against rare, fatal diseases? And how much weight, if any, should be given to outside appeals from patients, advocates and their political allies?

Typically, FDA approval requires two large studies or one study with a “very persuasive” effect on survival.

Amylyx’s data comes from one small, mid-stage trial that showed some benefit in slowing the disease, but which was marred by missing data, implementation errors and other problems, according to FDA reviewers.

Amylyx says follow-up data gathered after the study concluded shows the drug extended life. When the company followed patients who continued taking the drug, they survived about 10 months longer than patients who never took the drug, according to a new company analysis.

But FDA said Friday the new approach “suffers from the same interpretability challenges” as Amylyx’s initial study and that the new analysis “is not independent data.”

The FDA does not publicly explain its rationale for holding meetings. But some outside analysts believe the agency is hoping that more external input will strengthen its hand when it renders its final decision, expected by the end of the month.

Amylyx’s drug is a combination of two older drug ingredients: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine. The Cambridge, Massachusetts, company has patented the combination and says the chemicals work together to shield cells from premature death. Its co-founders first hit upon the combination as Brown University students.

Some ALS patients already take both pills. FDA approval would likely compel insurers to cover the treatment.

The FDA will hear again from patients and advocacy groups, such as I AM ALS, which has lobbied the FDA and Congress for more than two years to make the drug available. The group’s founder, Brian Wallach, said ALS patients, physicians and researchers believe that the company’s data warrants approval.

“Patients do their homework– we know this isn’t going to cure us,” said Wallach, who was diagnosed with ALS in 2017 and spoke through an interpreter. “But we also know it might keep us here until the next drug comes along and that one might be a cure.”

Wallach currently takes the part of Amylyx’s treatment that is available as a dietary supplement.

Despite the negative FDA review, there are several outside developments that could tip the FDA toward approval.

In June, Canadian regulators approved the drug for ALS patients, the first country to do so. That decision puts FDA regulators in a “precarious position,” says bioethicist Holly Fernandez-Lynch.

“They typically like to be out ahead when making approval decisions,” said Fernandez-Lynch, who teaches at the University of Pennsylvania. “They like to make the argument that they are not a barrier to patients accessing things that might help them.”

Shares of Amylyx fell more than 23% to close at $18 in trading Friday.


Follow Matthew Perrone on Twitter: @AP_FDAwriter


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


FILE - A person walks past an electronic stock board showing Japan's Nikkei 225 index and U.S. doll...
Associated Press

Business sentiments cool as cheap yen, costs weigh on Japan

TOKYO (AP) — Business sentiment among large manufacturers worsened for the third straight quarter, a Bank of Japan survey showed Monday, as the nation grappled with rising costs, the dropping value of the yen and restrictions on economic activity over the coronavirus pandemic. The headline measure for the “tankan,” measuring sentiment among large manufacturers, was […]
21 hours ago
FILE - King Charles III salutes as he leaves Westminster Abbey following the state funeral service ...
Associated Press

King Charles III to host South African leader in state visit

LONDON (AP) — King Charles III will welcome South African President Cyril Ramaphosa to the U.K. for three days of high-level talks next month, celebrating the first state visit of his reign with the leader of a Commonwealth member with close ties to the royal family. Ramaphosa has accepted Charles’s invitation for a state visit […]
21 hours ago
FILE - El Salvador's President Nayib Bukele participates in the closing ceremony of a congress for ...
Associated Press

In El Salvador, army surrounds town to root out gang

SAN SALVADOR, El Salvador (AP) — More than 2,000 soldiers and police surrounded and closed off a town in El Salvador Sunday in order to search for street gang members accused in a killing. The large-scale encirclement of the town of Comasagua is the latest example of heavy-handed tactics by the government to root out […]
21 hours ago
FILE - A boy diagnosed with cholera receives treatment at a cholera center in Anse D'Hainault, Hait...
Associated Press

Haiti reports cholera deaths for first time in 3 years

PORT-AU-PRINCE, Haiti (AP) — Haiti’s government on Sunday announced that at least eight people have died from cholera, raising concerns about a potentially fast-spreading scenario and reviving memories of an epidemic that killed nearly 10,000 people a decade ago. The cases – the first cholera deaths reported in three years – came in a community […]
21 hours ago
Associated Press

Madame Wu, restaurateur to Hollywood’s elite, dies at 106

LOS ANGELES (AP) — Sylvia Wu, whose famed Southern California restaurant drew Hollywood’s biggest stars for four decades, has died at age 106, according to a news report. Madame Wu’s Garden on Wilshire Boulevard in Santa Monica became a dining destination shortly after it opened in 1959, popular for its cuisine and pagoda-style decor featuring […]
21 hours ago
Associated Press

3 die when plane hits Minnesota home, but 2 in house unhurt

HERMANTOWN, Minn. (AP) — Three people aboard a small airplane died when it crashed into a house near a northern Minnesota airport, but the two people sleeping inside the home — and their cat — were unhurt. Hermantown Police said the Cessna 172 plane crashed into the second floor of the home just south of […]
21 hours ago

Sponsored Articles

Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Work at Zum Services...

Seattle Public Schools announces three-year contract with Zum

Seattle Public Schools just announced a three-year contract with a brand-new company to the Pacific Northwest to assist with their student transportation: Zum.
Swedish Cyberknife 900x506...

June is Men’s Health Month: Here’s Why It’s Important To Speak About Your Health

According to the Centers for Disease Control and Prevention, men in the United States, on average, die five years earlier than women.

Anacortes – A Must Visit Summertime Destination

While Anacortes is certainly on the way to the San Juan Islands (SJI), it is not just a destination to get to the ferry… Anacortes is a destination in and of itself!

Ready for your 2022 Alaskan Adventure with Celebrity Cruises?

Celebrity Cruises SPONSORED — A round-trip Alaska cruise from Seattle is an amazing treat for you and a loved one. Not only are you able to see and explore some of the most incredible and visually appealing natural sights on the planet, but you’re also able to relax and re-energize while aboard a luxury cruise […]
FDA still skeptical of ALS drug ahead of high-stakes meeting